Targeted drug ibrutinib shows promise against rare leukemia

NCT ID NCT01841723

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib (a targeted cancer drug)
What this could lead to: If it works, this could offer a new treatment option for people with hairy cell leukemia that has come back after previous therapy.
What could go wrong: This is a small, early-phase trial with only 44 people. The drug may not work for everyone, and side effects like bleeding or infection are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hairy cell leukemia hairy cell leukemia variant refractory hairy cell leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAIRY CELL LEUKEMIA HAIRY CELL LEUKEMIA VARIANT RECURRENT HAIRY CELL LEUKEMIA RECURRENT HAIRY CELL LEUKEMIA VARIANT

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.